Reform passes House with pros, cons for pharma

The House Energy and Commerce Committee attached a provision for 12 years of biologic drug exclusivity to broader healthcare reform legislation. That's despite calls from President Obama for seven years of protection and Rep. Henry Waxman's five-year plan. The longer term of exclusivity can also be extended for a variety of reasons, including dosage changes, delivery-method improvements, and so on. Branded drugmakers should be cheered by the protections, though they're already drawing fire from generics makers and some healthcare reform advocates. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.